ADAR1 Capital Management, LLC purchased $2K of INM (indirect holdings)
ADAR1 Capital Management, LLC purchased 1,000 indirectly-held shares of InMed Pharmaceuticals Inc. (INM) at $1.56 on 2026-07-15.
How this was made
The 30-second read
Why it matters
The newest concrete fact is the specific open-market purchase details (1,000 shares at $1.5550) and the updated holdings (801,000 shares). This may slightly influence sentiment but does not provide new operational or financial guidance.
Market read
Traders may note the insider buy for sentiment, but the disclosed size is too small to be a standalone catalyst.
What to watch
The transaction is explicitly indirect and small in dollar terms, and the filing notes no 10b5-1 plan, which can increase interpretation noise without adding fundamental information.
Background
This is an SEC Form 4 insider transaction disclosure for InMed Pharmaceuticals, reported by ADAR1 Capital Management as a 10% owner with indirect holdings.
Ticker impact
InMed Pharmaceuticals disclosed an open-market purchase by 10% owner ADAR1 Capital Management of 1,000 shares at $1.5550 on 2026-07-15.
Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around the filing.
The filing is primary-source and specific, but the transaction value ($1,555) is small and there is no 10b5-1 plan or other accompanying fundamental catalyst in the text.
Market effects
No sector-level read-across provided; this is company-specific insider activity.
None indicated.
None indicated.
Counterpoint
The buy could be routine portfolio rebalancing or indirect holdings mechanics rather than a strong forward-looking signal.
Key entities
- issuerInMed Pharmaceuticals Inc.
Subject of the Form 4 insider transaction disclosure (INM).
- insiderADAR1 Capital Management, LLC
10% owner reporting an indirect open-market purchase of INM shares.